Could a common supplement help a rare disease? early trial begins

NCT ID NCT07572825

Recruiting now Disease control Sponsor: Eva Morava-Kozicz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing the safety of a dietary supplement called NMN in 8 people with a rare genetic disorder known as DHDDS-CDG, which affects movement and development. Participants will take 250 mg of NMN daily for 6 months, with an optional 12-month follow-up. The main goal is to see if NMN is safe and tolerable, and to gather information that may help doctors decide whether to recommend it for this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nicotinamide mononucleotide (NMN), a dietary supplement

What this could lead to

If it works, this could point toward a way to manage symptoms of DHDDS-CDG, a rare genetic disorder that affects movement and development.

What could go wrong

This is a very small, early-phase trial with only 8 participants. It primarily tests safety, not effectiveness, so it may not lead to a proven treatment. NMN is a supplement and its benefits for this condition are unproven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates